Published in J Neurosurg on February 01, 2005
Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology (2010) 2.31
Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest (2011) 1.54
Treatment of Parkinson's disease with trophic factors. Neurotherapeutics (2008) 1.35
Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery. Pharm Res (2009) 1.32
Long-term transgene expression in the central nervous system using DNA nanoparticles. Mol Ther (2009) 1.32
Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. Stereotact Funct Neurosurg (2011) 1.30
Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J Neurosci (2010) 1.20
Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin. J Cell Biol (2011) 1.18
RET signaling does not modulate MPTP toxicity but is required for regeneration of dopaminergic axon terminals. Proc Natl Acad Sci U S A (2007) 1.11
Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta (2008) 1.08
Neurodegeneration and cell replacement. Philos Trans R Soc Lond B Biol Sci (2008) 1.01
Aging reveals a role for nigral tyrosine hydroxylase ser31 phosphorylation in locomotor activity generation. PLoS One (2009) 1.00
CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. Cell Transplant (2011) 0.99
Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease. Neurobiol Dis (2007) 0.98
Pathways of infusate loss during convection-enhanced delivery into the putamen nucleus. Stereotact Funct Neurosurg (2013) 0.96
Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease. Mov Disord (2015) 0.96
Spheramine for treatment of Parkinson's disease. Neurotherapeutics (2008) 0.96
Intraputamenal infusion of exogenous neurturin protein restores motor and dopaminergic function in the globus pallidus of MPTP-lesioned rhesus monkeys. Cell Transplant (2008) 0.95
Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease. Curr Neuropharmacol (2007) 0.94
Enhanced delivery and bioactivity of the neurturin neurotrophic factor through focused ultrasound-mediated blood--brain barrier opening in vivo. J Cereb Blood Flow Metab (2015) 0.92
Extrastriatal dopaminergic circuits of the Basal Ganglia. Front Neuroanat (2010) 0.92
Future of cell and gene therapies for Parkinson's disease. Ann Neurol (2008) 0.92
GDNF-transfected macrophages produce potent neuroprotective effects in Parkinson's disease mouse model. PLoS One (2014) 0.91
Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease. Brain Behav (2013) 0.91
The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue? Front Pharmacol (2014) 0.90
The involvement of BDNF, NGF and GDNF in aging and Alzheimer's disease. Aging Dis (2015) 0.90
Potential drugs and methods for preventing or delaying the progression of Huntington's disease. Recent Pat CNS Drug Discov (2011) 0.89
Calcitriol imparts neuroprotection in vitro to midbrain dopaminergic neurons by upregulating GDNF expression. PLoS One (2013) 0.89
GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's disease. Front Neuroanat (2015) 0.87
Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease. Neural Regen Res (2014) 0.86
Future applications: gene therapy. Neurosurg Clin N Am (2009) 0.85
Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons. PLoS One (2009) 0.85
Nigral GFRα1 infusion in aged rats increases locomotor activity, nigral tyrosine hydroxylase, and dopamine content in synchronicity. Mol Neurobiol (2013) 0.85
Tetanus toxin C-fragment: the courier and the cure? Toxins (Basel) (2010) 0.84
Salvianolic acid B attenuates toxin-induced neuronal damage via Nrf2-dependent glial cells-mediated protective activity in Parkinson's disease models. PLoS One (2014) 0.84
Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases. Int J Mol Sci (2014) 0.84
Pathways towards an effective immunotherapy for Parkinson's disease. Expert Rev Neurother (2011) 0.84
Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease. BMC Neurosci (2009) 0.83
Dopamine neuron stimulating actions of a GDNF propeptide. PLoS One (2010) 0.83
Calcitriol promotes augmented dopamine release in the lesioned striatum of 6-hydroxydopamine treated rats. Neurochem Res (2014) 0.82
alpha-Synuclein: a therapeutic target for Parkinson's disease? Pharmacol Res (2008) 0.82
Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study. J Neurol Neurosurg Psychiatry (2007) 0.82
Targeting the progression of Parkinson's disease. Curr Neuropharmacol (2009) 0.82
A novel immunoprecipitation strategy identifies a unique functional mimic of the glial cell line-derived neurotrophic factor family ligands in the pathogen Trypanosoma cruzi. Infect Immun (2008) 0.82
Glial cell line-derived neurotrophic factor is crucial for long-term maintenance of the nigrostriatal system. Neuroscience (2010) 0.81
Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain. Neuropharmacology (2010) 0.81
Pharmacological MRI (phMRI) monitoring of treatment in hemiparkinsonian rhesus monkeys. Cell Transplant (2008) 0.81
GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease. Neurosci Lett (2006) 0.81
Peripheral stimulation in treating Parkinson's disease: Is it a realistic idea or a romantic whimsicality? Intractable Rare Dis Res (2012) 0.80
Glial cell-line derived neurotrophic factor (GDNF) replacement attenuates motor impairments and nigrostriatal dopamine deficits in 12-month-old mice with a partial deletion of GDNF. Pharmacol Biochem Behav (2013) 0.80
The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease. Int J Mol Sci (2011) 0.80
Research on Parkinson disease. J Neurosurg (2005) 0.79
Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's Disease. PLoS One (2016) 0.79
Evaluation of the physical and in vitro protective activity of three synthetic peptides derived from the pro- and mature GDNF sequence. Neuropeptides (2011) 0.79
Effects of GDF5 overexpression on embryonic rat dopaminergic neurones in vitro and in vivo. J Neural Transm (Vienna) (2010) 0.79
Effects of aging on glutamate neurotransmission in the substantia nigra of Gdnf heterozygous mice. Neurobiol Aging (2014) 0.78
Sorting protein-related receptor SorLA controls regulated secretion of glial cell line-derived neurotrophic factor. J Biol Chem (2011) 0.77
Tricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system. Exp Neurol (2015) 0.77
Dynamic changes in dopamine neuron function after DNSP-11 treatment: effects in vivo and increased ERK 1/2 phosphorylation in vitro. Peptides (2014) 0.77
Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications. Pharmaceuticals (Basel) (2012) 0.77
Autologous transplantation of GDNF-expressing mesenchymal stem cells protects against MPTP-induced damage in cynomolgus monkeys. Sci Rep (2013) 0.77
Glial Cell Line-Derived Neurotrophic Factor Family Members Reduce Microglial Activation via Inhibiting p38MAPKs-Mediated Inflammatory Responses. J Neurodegener Dis (2014) 0.77
Neurturin protects against 6-hydroxydopamine-induced reductions in evoked dopamine overflow in rat striatum. Neurochem Int (2010) 0.77
Neurological disorders and neural regeneration, with special reference to Parkinson's disease and cerebral ischemia. J Artif Organs (2009) 0.77
Effects of glial cell line-derived neurotrophic factor on microRNA expression in a 6-hydroxydopamine-injured dopaminergic cell line. J Neural Transm (Vienna) (2013) 0.76
Can Parkinson's disease be cured by stimulating neurogenesis? J Clin Invest (2015) 0.76
GDNF gene delivery via a 2-(dimethylamino)ethyl methacrylate based cyclized knot polymer for neuronal cell applications. ACS Chem Neurosci (2013) 0.76
Glial cell line-derived neurotrophic factor partially ameliorates motor symptoms without slowing neurodegeneration in mice with respiratory chain-deficient dopamine neurons. Cell Transplant (2012) 0.76
Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease. J Neurosci Methods (2015) 0.75
Treating non-motor symptoms of Parkinson's disease with transplantation of stem cells. Expert Rev Neurother (2015) 0.75
Systemic injection of AAV9-GDNF provides modest functional improvements in the SOD1(G93A) ALS rat but has adverse side effects. Gene Ther (2017) 0.75
Neurotrophic Factors and Their Potential Applications in Tissue Regeneration. Arch Immunol Ther Exp (Warsz) (2015) 0.75
Neurotrophic factor therapy for Parkinson's disease: past, present and future. Neural Regen Res (2016) 0.75
A synthetic five amino acid propeptide increases dopamine neuron differentiation and neurochemical function. Neuropeptides (2012) 0.75
Implementation of a chronic unilateral intraparenchymal drug delivery system in a swine model. J Neurosci Methods (2014) 0.75
Towards Clinical Application of Neurotrophic Factors to the Auditory Nerve; Assessment of Safety and Efficacy by a Systematic Review of Neurotrophic Treatments in Humans. Int J Mol Sci (2016) 0.75
Regenerative medicine for Parkinson's disease. Neurol Med Chir (Tokyo) (2015) 0.75
Insights from mathematical modeling for convection-enhanced intraputamenal delivery of GDNF. Med Biol Eng Comput (2017) 0.75
The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease. PLoS One (2017) 0.75
Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet (2005) 10.11
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Neuropathologic substrate of mild cognitive impairment. Arch Neurol (2006) 6.26
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res (2003) 3.71
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell (2007) 3.37
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res (2005) 2.98
TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol (2007) 2.97
Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol (2008) 2.44
Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J Neuropathol Exp Neurol (2006) 2.43
Hippocampal sclerosis in advanced age: clinical and pathological features. Brain (2011) 2.16
Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther (2010) 2.09
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain (2002) 1.99
PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther (2009) 1.97
Dissociation of automatic and strategic lexical-semantics: functional magnetic resonance imaging evidence for differing roles of multiple frontotemporal regions. J Neurosci (2006) 1.92
Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther (2006) 1.88
Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 1.86
Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol (2009) 1.73
Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther (2011) 1.72
Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase. Dig Dis Sci (2007) 1.72
Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. J Neuropathol Exp Neurol (2009) 1.66
Lifelong bilingualism maintains neural efficiency for cognitive control in aging. J Neurosci (2013) 1.62
Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol (2011) 1.62
Comparing functional profiles of children with hemiplegic and diplegic cerebral palsy in GMFCS Levels I and II: Are separate classifications needed? Dev Med Child Neurol (2006) 1.59
Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res (2007) 1.58
Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia. Am J Med Genet A (2008) 1.57
Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res (2006) 1.56
Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol Pathol (2007) 1.52
Substantia nigra vulnerability after a single moderate diffuse brain injury in the rat. Exp Neurol (2011) 1.52
Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim Biophys Acta (2008) 1.46
Improved ceramic-based multisite microelectrode for rapid measurements of L-glutamate in the CNS. J Neurosci Methods (2002) 1.45
Age-related slowing of task switching is associated with decreased integrity of frontoparietal white matter. Neurobiol Aging (2008) 1.44
Systemic metabolic effects of combined insulin-like growth factor-I and growth hormone therapy in patients who have sustained acute traumatic brain injury. J Neurosurg (2006) 1.43
Chronic second-by-second measures of L-glutamate in the central nervous system of freely moving rats. J Neurochem (2007) 1.42
Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol (2006) 1.42
Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease. Acta Neuropathol (2013) 1.41
Outcome assessments in children with cerebral palsy, part I: descriptive characteristics of GMFCS Levels I to III. Dev Med Child Neurol (2007) 1.40
Huntingtin interacting protein 14 is an oncogenic human protein: palmitoyl acyltransferase. Oncogene (2004) 1.37
A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J Pharmacol Exp Ther (2010) 1.37
Acute cocaine differentially alters accumbens and striatal dopamine clearance in low and high cocaine locomotor responders: behavioral and electrochemical recordings in freely moving rats. J Pharmacol Exp Ther (2002) 1.35
Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J Comp Neurol (2003) 1.34
Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg (2007) 1.34
Rapid assessment of in vivo cholinergic transmission by amperometric detection of changes in extracellular choline levels. Eur J Neurosci (2004) 1.30
Individual differences in cocaine-induced locomotor sensitization in low and high cocaine locomotor-responding rats are associated with differential inhibition of dopamine clearance in nucleus accumbens. J Pharmacol Exp Ther (2003) 1.30
Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology (2010) 1.29
Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. Carcinogenesis (2010) 1.28
A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood (2009) 1.28
Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys. J Neurosci (2003) 1.25
Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther (2011) 1.24
Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res (2008) 1.22
Alterations in multiple measures of white matter integrity in normal women at high risk for Alzheimer's disease. Neuroimage (2010) 1.20
Two N-myristoyltransferase isozymes play unique roles in protein myristoylation, proliferation, and apoptosis. Mol Cancer Res (2005) 1.20
The Pim protein kinases regulate energy metabolism and cell growth. Proc Natl Acad Sci U S A (2010) 1.20
Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration. Mol Cancer Res (2011) 1.18
Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol (2004) 1.18
Stereotatic radiosurgery of 468 brain metastases < or =2 cm: implications for SRS dose and whole brain radiation therapy. Int J Radiat Oncol Biol Phys (2004) 1.18
Facilitation and restoration of cognitive function in primate prefrontal cortex by a neuroprosthesis that utilizes minicolumn-specific neural firing. J Neural Eng (2012) 1.17
Ceramic-based multisite microelectrode arrays for simultaneous measures of choline and acetylcholine in CNS. Biosens Bioelectron (2007) 1.17
Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity. Ann Neurol (2008) 1.17
Development of a syngeneic in vivo tumor model and its use in evaluating a novel P-glycoprotein modulator, PGP-4008. Oncol Res (2003) 1.16
Rapid microelectrode measurements and the origin and regulation of extracellular glutamate in rat prefrontal cortex. J Neurochem (2010) 1.15
Alzheimer's-type neuropathology in the precuneus is not increased relative to other areas of neocortex across a range of cognitive impairment. Neurosci Lett (2008) 1.15
Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem (2009) 1.14
Diffuse brain injury elevates tonic glutamate levels and potassium-evoked glutamate release in discrete brain regions at two days post-injury: an enzyme-based microelectrode array study. J Neurotrauma (2010) 1.14
Transport mechanisms governing serotonin clearance in vivo revealed by high-speed chronoamperometry. J Neurosci Methods (2005) 1.14
Discovery and characterization of inhibitors of human palmitoyl acyltransferases. Mol Cancer Ther (2006) 1.13
Arteriolosclerosis that affects multiple brain regions is linked to hippocampal sclerosis of ageing. Brain (2013) 1.13
Outcome assessments in children with cerebral palsy, part II: discriminatory ability of outcome tools. Dev Med Child Neurol (2007) 1.12
Neuronal fiber pathway abnormalities in autism: an initial MRI diffusion tensor tracking study of hippocampo-fusiform and amygdalo-fusiform pathways. J Int Neuropsychol Soc (2008) 1.12
Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med (2003) 1.11
Facilitation of memory encoding in primate hippocampus by a neuroprosthesis that promotes task-specific neural firing. J Neural Eng (2013) 1.09
Progenitor proliferation in the adult hippocampus and substantia nigra induced by glial cell line-derived neurotrophic factor. Exp Neurol (2005) 1.09
ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol (2014) 1.07
Cellular palmitoylation and trafficking of lipidated peptides. J Lipid Res (2007) 1.07
Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys. J Neurochem (2002) 1.07
Functional MRI studies in awake rhesus monkeys: methodological and analytical strategies. J Neurosci Methods (2002) 1.07
White matter integrity and vulnerability to Alzheimer's disease: preliminary findings and future directions. Biochim Biophys Acta (2011) 1.07
Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology (2005) 1.07
Columnar processing in primate pFC: evidence for executive control microcircuits. J Cogn Neurosci (2012) 1.07
Age-related changes in glutamate release in the CA3 and dentate gyrus of the rat hippocampus. Neurobiol Aging (2009) 1.06
Nicotinic acetylcholine receptors interact with dopamine in induction of striatal long-term depression. J Neurosci (2002) 1.06
Ceramic-based multisite electrode arrays for chronic single-neuron recording. IEEE Trans Biomed Eng (2004) 1.06
Kinetic analysis of striatal clearance of exogenous dopamine recorded by chronoamperometry in freely-moving rats. J Neurosci Methods (2002) 1.06
Association between male gender and cortical Lewy body pathology in large autopsy series. J Neurol (2010) 1.06
Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma. Mol Cancer Ther (2013) 1.05
Trophic factor distribution predicts functional recovery in parkinsonian monkeys. Ann Neurol (2005) 1.05
Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra. J Neurochem (2004) 1.05
Second-by-second analysis of alpha 7 nicotine receptor regulation of glutamate release in the prefrontal cortex of awake rats. Synapse (2009) 1.05